Literature DB >> 21397598

Adenovirus mediated homozygous endometrial epithelial Pten deletion results in aggressive endometrial carcinoma.

Ayesha Joshi1, Lora Hedrick Ellenson.   

Abstract

Pten is the most frequently mutated gene in uterine endometriod carcinoma (UEC) and its precursor complex atypical hyperplasia (CAH). Because the mutation frequency is similar in CAH and UEC, Pten mutations are thought to occur relatively early in endometrial tumorigenesis. Previous work from our laboratory using the Pten(+/-) mouse model has demonstrated somatic inactivation of the wild type allele of Pten in both CAH and UEC. In the present study, we injected adenoviruses expressing Cre into the uterine lumen of adult Pten floxed mice in an attempt to somatically delete both alleles of Pten specifically in the endometrium. Our results demonstrate that biallelic inactivation of Pten results in an increased incidence of carcinoma as compared to the Pten(+/-) mouse model. In addition, the carcinomas were more aggressive with extension beyond the uterus into adjacent tissues and were associated with decreased expression of nuclear ERα as compared to associated CAH. Primary cultures of epithelial and stromal cells were prepared from uteri of Pten floxed mice and Pten was deleted in vitro using Cre expressing adenovirus. Pten deletion was evident in both the epithelial and stromal cells and the treatment of the primary cultures with estrogen had different effects on Akt activation as well as Cyclin D3 expression in the two purified components. This study demonstrates that somatic biallelic inactivation of Pten in endometrial epithelium in vivo results in an increased incidence and aggressiveness of endometrial carcinoma compared to mice carrying a germline deletion of one allele and provides an important in vivo and in vitro model system for understanding the genetic underpinnings of endometrial carcinoma.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21397598      PMCID: PMC3103602          DOI: 10.1016/j.yexcr.2011.03.006

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  39 in total

1.  Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.

Authors:  Xiaoqian Ma; Angelique C Ziel-van der Made; Binha Autar; Hetty A van der Korput; Marcel Vermeij; Petra van Duijn; Kitty B Cleutjens; Ronald de Krijger; Paul Krimpenfort; Anton Berns; Theo H van der Kwast; Jan Trapman
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

Review 2.  Estrogen receptor null mice: what have we learned and where will they lead us?

Authors:  J F Couse; K S Korach
Journal:  Endocr Rev       Date:  1999-06       Impact factor: 19.871

3.  A new mouse model of pancreatic cancer: PTEN gets its Akt together.

Authors:  Anirban Maitra; Ralph H Hruban
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

4.  Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo.

Authors:  Melissa M Fraser; Xiaoyan Zhu; Chang-Hyuk Kwon; Erik J Uhlmann; David H Gutmann; Suzanne J Baker
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

5.  Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice.

Authors:  Anna Vilgelm; Zenglin Lian; Hong Wang; Stephen L Beauparlant; Andres Klein-Szanto; Lora Hedrick Ellenson; Antonio Di Cristofano
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

6.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems.

Authors:  K Podsypanina; L H Ellenson; A Nemes; J Gu; M Tamura; K M Yamada; C Cordon-Cardo; G Catoretti; P E Fisher; R Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

7.  Tissue compartment-specific estrogen receptor-alpha participation in the mouse uterine epithelial secretory response.

Authors:  D L Buchanan; T Setiawan; D B Lubahn; J A Taylor; T Kurita; G R Cunha; P S Cooke
Journal:  Endocrinology       Date:  1999-01       Impact factor: 4.736

8.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

9.  Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence.

Authors:  Tanri Shiozawa; Tsutomu Miyamoto; Hiroyasu Kashima; Kohzo Nakayama; Toshio Nikaido; Ikuo Konishi
Journal:  Oncogene       Date:  2004-11-11       Impact factor: 9.867

10.  Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias.

Authors:  G L Maxwell; J I Risinger; C Gumbs; H Shaw; R C Bentley; J C Barrett; A Berchuck; P A Futreal
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

View more
  12 in total

1.  Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy.

Authors:  Deanna M Janzen; Miguel A Rosales; Daniel Y Paik; Daniel S Lee; Daniel A Smith; Owen N Witte; M Luisa Iruela-Arispe; Sanaz Memarzadeh
Journal:  Cancer Res       Date:  2013-06-06       Impact factor: 12.701

2.  Activated mutant p110α causes endometrial carcinoma in the setting of biallelic Pten deletion.

Authors:  Ayesha Joshi; Christopher Miller; Suzanne J Baker; Lora H Ellenson
Journal:  Am J Pathol       Date:  2015-02-16       Impact factor: 4.307

3.  A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.

Authors:  Hailing Cheng; Pixu Liu; Fan Zhang; Erbo Xu; Lynn Symonds; Carolynn E Ohlson; Roderick T Bronson; Sauveur-Michel Maira; Emmanuelle Di Tomaso; Jane Li; Andrea P Myers; Lewis C Cantley; Gordon B Mills; Jean J Zhao
Journal:  Cancer Res       Date:  2013-12-09       Impact factor: 12.701

Review 4.  Influence of AKT on progesterone action in endometrial diseases.

Authors:  Irene I Lee; J Julie Kim
Journal:  Biol Reprod       Date:  2014-08-06       Impact factor: 4.285

5.  Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.

Authors:  Deanna M Janzen; Daniel Y Paik; Miguel A Rosales; Brian Yep; Donghui Cheng; Owen N Witte; Huseyin Kayadibi; Christopher M Ryan; Michael E Jung; Kym Faull; Sanaz Memarzadeh
Journal:  Mol Cancer Ther       Date:  2013-11-12       Impact factor: 6.261

6.  Progression inference for somatic mutations in cancer.

Authors:  Leif E Peterson; Tatiana Kovyrshina
Journal:  Heliyon       Date:  2017-04-11

7.  Kras activation in endometrial organoids drives cellular transformation and epithelial-mesenchymal transition.

Authors:  Yoshiaki Maru; Naotake Tanaka; Yasutoshi Tatsumi; Yuki Nakamura; Makiko Itami; Yoshitaka Hippo
Journal:  Oncogenesis       Date:  2021-06-25       Impact factor: 7.485

8.  MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location.

Authors:  Tejas S Tirodkar; Raluca A Budiu; Esther Elishaev; Lixin Zhang; Jyothi T Mony; Joan Brozick; Robert P Edwards; Anda M Vlad
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

9.  Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma.

Authors:  Laura P Brandt; Joachim Albers; Tomas Hejhal; Antonella Catalano; Peter J Wild; Ian J Frew
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

10.  The uterine epithelial loss of Pten is inefficient to induce endometrial cancer with intact stromal Pten.

Authors:  Xiaohuan Liang; Takiko Daikoku; Jumpei Terakawa; Yuya Ogawa; Ayesha R Joshi; Lora H Ellenson; Xiaofei Sun; Sudhansu K Dey
Journal:  PLoS Genet       Date:  2018-08-24       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.